RUNX1 and acute myeloid leukemia: Seventy patients benefited from molecular analysis with the local high throughput sequencing AML minimal panel searching for mutations of NPM1, FLT3ITD, IDH1, IDH2, ASXL1, RUNX1, TP53 at diagnosis.